Filing Details
Autolus Therapeutics plc (NASDAQ:AUTL) filed a Form 8-K with the Securities and Exchange Commission on August 03, 2026, disclosing a material event.
8k filedNASDAQ:AUTL
Autolus Therapeutics plc (AUTL) Reports Material Event to SEC
Filing Details Autolus Therapeutics plc (NASDAQ:AUTL) filed a Form 8-K with the Securities and Exchange Commission on August 03, 2026, disclosing a material event. Market Context…
Market Context
Autolus Therapeutics plc's stock currently trades at $1.82 with a market capitalization of $424.5M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Autolus Therapeutics plc's stock.
All SEC filings for Autolus Therapeutics plc are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View AUTL Stock Page
Frequently Asked Questions
Where can I read AUTL's SEC filings?
Browse all filings on our AUTL SEC filings page.
What types of SEC filings does Autolus Therapeutics plc file?
Public companies like Autolus Therapeutics plc file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.